Upgrade to SI Premium - Free Trial

After-Hours Stock Movers 03/02: (HTBX) (MRVI) (AMBA) Higher; (ARNA) (BGS) (MGY) Lower (more...)

March 2, 2021 5:32 PM

Today's After-Hours Movers

Heat Biologics (NASDAQ: HTBX) 23.3% HIGHER; Cantor Fitzgerald initiates coverage with an Overweight rating and a price target of $22.00.

Maravai LifeSciences (NASDAQ: MRVI) 20.5% HIGHER; reported Q4 EPS of $0.13, $0.02 better than the analyst estimate of $0.11. Revenue for the quarter came in at $98.4 million versus the consensus estimate of $89.02 million. Maravai LifeSciences sees FY2021 EPS of $0.80-$0.90, versus the consensus of $0.61. Maravai LifeSciences sees FY2021 revenue of $580-630 million, versus the consensus of $429.55 million.

Ambarella (NASDAQ: AMBA) 8.9% HIGHER; reported Q4 EPS of $0.14, $0.06 better than the analyst estimate of $0.08. Revenue for the quarter came in at $62.1 million versus the consensus estimate of $58.14 million. Ambarella sees Q1 2022 revenue of $67-70 million, versus the consensus of $56.4 million.

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) 7.6% LOWER; announced topline results from the randomized, double-blind, placebo-controlled Phase 2b CAPTIVATE clinical trial evaluating three doses of olorinab, a novel, oral, peripherally acting, highly selective, full agonist of the cannabinoid receptor 2 (CB2), in participants with abdominal pain due to Irritable Bowel Syndrome (IBS). The CAPTIVATE trial randomized a total of 273 participants and was conducted in study sites across the United States. The results show that, although olorinab was well tolerated, it did not meet the primary efficacy endpoint of statistically significant improvement in the overall AAPS from baseline to week 12.

B&G Foods (NYSE: BGS) 6.7% LOWER; reported Q4 EPS of $0.35, $0.10 worse than the analyst estimate of $0.45. Revenue for the quarter came in at $510.2 million versus the consensus estimate of $531.12 million. B&G Foods sees FY2021 revenue of $2.05-2.1 billion, versus the consensus of $2.03 billion.

Magnolia Oil & Gas Corporation (NYSE: MGY) 6% LOWER; announced that it has commenced an underwritten public offering of an aggregate 17,000,000 shares of the Company’s Class A common stock by certain affiliates of EnerVest, Ltd.. The Selling Stockholders expect to grant the underwriters a 30-day option to purchase up to an aggregate additional 2,550,000 shares of Class A Common Stock. Magnolia will not sell any shares of its Class A Common Stock in the Offering or receive any proceeds from the Offering.

Sorrento Therapeutics, Inc. (Nasdaq: SRNE) 5.9% HIGHER; announced today that it has received clearance from the FDA for its Investigational New Drug application (IND) for its Phase 1 study of the safety and pharmacokinetics of intranasal (IN) STI-2099 (COVIDROPS) in both healthy volunteers and patients with mild COVID-19.

Lyft (NASDAQ: LYFT) 4.8% HIGHER; Announces Positive Update; Average Daily Rideshare Ride Volume in February rose 5.4%, Sees Improved EBITDA Loss in Q1.

Capitol Investment Corp. V (NYSE: CAP) 4.8% HIGHER; Doma, formerly known as States Title, a leading force for disruptive change in the real estate industry, has entered into a definitive business combination agreement with SPAC Capitol Investment Corp. V (NYSE: CAP).

Ross Stores (NASDAQ: ROST) 4.2% LOWER; reported Q4 EPS of $0.67, $0.33 worse than the analyst estimate of $1.00. Revenue for the quarter came in at $4.25 billion versus the consensus estimate of $4.27 billion. Ross Stores sees Q1 2021 EPS of $0.74-$0.86, versus the consensus of $0.89.

Big 5 Sporting Goods (NASDAQ: BGFV) 3.8% HIGHER; reported Q4 EPS of $0.95, $0.05 better than the analyst estimate of $0.90. Revenue for the quarter came in at $290.6 million versus the consensus estimate of $290.5 million. Big 5 Sporting Goods sees Q1 2021 EPS of $0.47-$0.53, versus the consensus of $0.23.

Fiverr International Ltd. (NYSE: FVRR) 3.8% LOWER; announced today the commencement of an underwritten public offering of $700,000,000 of its ordinary shares.

PLx Pharma Inc. (NASDAQ: PLXP) 3.7% LOWER; intends to offer shares of its common stock for sale in an underwritten public offering. In addition, the Company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissions.

Rocket Companies, Inc. (NYSE: RKT) 2.4% LOWER; gives back some of today's 71% intra-day gains.

Categories

Special Reports